{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:06:00Z","timestamp":1793160360044,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.semarthrit.2018.10.018","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T21:38:53Z","timestamp":1541194733000},"page":"1087-1092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs"],"prefix":"10.1016","volume":"48","author":[{"given":"Gabriela","family":"Schmajuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashif","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Shiboski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Gianfrancesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0905","authenticated-orcid":false,"given":"Zara","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishita","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urmimala","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Adams","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinoos","family":"Yazdany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.semarthrit.2018.10.018_bib0001","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.10.018_bib0002","first-page":"671","article-title":"Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience","volume":"35","author":"Mecoli","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.10.018_bib0003","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00002281-199905000-00004","article-title":"Prevention of infectious complications in rheumatic disease patients: immunization, pneumocystis carinii prophylaxis, and screening for latent infections","volume":"11","author":"Singer","year":"1999","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.10.018_bib0004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.medmal.2014.01.007","article-title":"Groupe de recherche respiratoire en reanimation en onco-h\u00e9matologie (Grrr-OH). Update on pulmonary pneumocystis jirovecii infection in non-HIV patients","volume":"44","author":"Roux","year":"2014","journal-title":"M\u00e9decine et Maladies Infectieuses"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.10.018_bib0005","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3899\/jrheum.091426","article-title":"Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases?","volume":"37","author":"Stamp","year":"2010","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.10.018_bib0006","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10067-006-0441-9","article-title":"Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review","volume":"26","author":"Falagas","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.10.018_bib0007","first-page":"1186","article-title":"Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis\/dermatomyositis or systemic lupus erythematosus","volume":"23","author":"Kadoya","year":"1996","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2018.10.018_bib0008","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/339548","article-title":"Opportunistic infections in patients with and patients without acquired Immunodeficiency Syndrome","volume":"34","author":"Sepkowitz","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.10.018_bib0009","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.23822","article-title":"When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases","volume":"59","author":"Suryaprasad","year":"2008","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.semarthrit.2018.10.018_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005590.pub3","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"10","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.10.018_bib0011","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.10.018_bib0012","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","article-title":"Increased incidence of interstitial pneumonia by CHOP combined with rituximab","volume":"87","author":"Ennishi","year":"2008","journal-title":"Int J Hematol"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.10.018_bib0013","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/bmjqs-2012-000946","article-title":"Adverse drug events caused by serious medication administration errors","volume":"21","author":"Sawarkar","year":"2012","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.semarthrit.2018.10.018_bib0014","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2018.10.018_bib0015","first-page":"437","article-title":"Fiducial limits for the Poisson distribution","volume":"28","author":"Garwood","year":"1936","journal-title":"Biometrica"},{"key":"10.1016\/j.semarthrit.2018.10.018_bib0016","doi-asserted-by":"crossref","DOI":"10.1093\/jpids\/pix052","article-title":"Incidence of pneumocystis jirovecii and adverse events associated with pneumocystis prophylaxis in children receiving glucocorticoids","author":"Basiaga","year":"2017","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.10.018_bib0017","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3899\/jrheum.090843","article-title":"Christopher-stine L: a survey of rheumatologists' practice for prescribing pneumocystis prophylaxis","volume":"37","author":"Cettomai","year":"2010","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2018.10.018_bib0018","doi-asserted-by":"crossref","first-page":"1242.e11","DOI":"10.1016\/j.amjmed.2014.07.010","article-title":"Incidence of pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients","volume":"127","author":"Fillatre","year":"2014","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2018.10.018_bib0019","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","article-title":"Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis","volume":"77","author":"Kronbichler","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.10.018_bib0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamadermatol.2017.6484","article-title":"Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-analysis","volume":"154","author":"Tangamornsuksan","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.semarthrit.2018.10.018_bib0021","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (Co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis","volume":"335","author":"Stegeman","year":"1996","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.10.018_bib0022","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/PTS.0b013e3181dcae06","article-title":"Outpatient adverse drug events identified by screening electronic health records","volume":"6","author":"Gandhi","year":"2010","journal-title":"J Patient Saf"},{"issue":"12","key":"10.1016\/j.semarthrit.2018.10.018_bib0023","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/acr.23089","article-title":"Rheumatology informatics system for effectiveness: a national informatics-enabled registry for quality improvement","volume":"68","author":"Yazdany","year":"2016","journal-title":"Arthr Care Res"},{"key":"10.1016\/j.semarthrit.2018.10.018_bib0024","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3899\/jrheum.081270","article-title":"A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis","volume":"36","author":"Mori","year":"2009","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.10.018_bib0025","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ajic.2015.11.012","article-title":"Pneumocystis pneumonia outbreak among renal transplant recipients at a North American transplant center: risk factors and implications for infection control","volume":"44","author":"Mulpuru","year":"2016","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.semarthrit.2018.10.018_bib0026","first-page":"903","article-title":"Building a time-saving and adaptable tool to report adverse drug events","volume":"192","author":"Par\u00e8s","year":"2013","journal-title":"Stud Health Technol Inform"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.10.018_bib0027","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jamainternmed.2016.8185","article-title":"Clarifying a \u201cpenicillin\u201d allergya teachable moment","volume":"177","author":"Vaisman","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.semarthrit.2018.10.018_bib0028","first-page":"892","article-title":"Shared decision making and the concept of equipoise: the competencies of involving patients in health care choices","volume":"50","author":"Elwyn","year":"2000","journal-title":"Br J Gen Pract"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218302634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218302634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T10:56:11Z","timestamp":1605351371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017218302634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0049017218302634"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.10.018","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}